EKF Diagnostics exhibits new POC testing tech at Arab Health 2014

EKF Diagnostics, the global in vitro diagnostics business, will exhibit two newly introduced point-of-care (POC) testing analyzers for rapidly assessing diabetes and related conditions. The Quo-Lab® glycated haemoglobin (HbA1c) analyzer and STAT-Site® M ß-HB will both be demonstrated on the Welsh Assembly Government Stand Z1D30 in Zabeel Hall 1, Arab Health, Dubai International Convention & Exhibition Centre, 27 – 30 January 2014.

Although only launched in July 2012, close to 1,300 Quo-Lab® HbA1c analyzers were sold globally in 2013, 60 of which are now installed in Lebanon for near-patient measurement and diabetes monitoring. HbA1c monitoring is increasingly used in detecting and managing diabetes, and Quo-Lab® provides highly accurate, affordable, and easy-to-use technology, which uses just 4 µL of venous or finger-prick blood to deliver lab-accurate results within four minutes.

Small and lightweight, Quo-Lab® is explicitly designed to meet the needs of clinics and laboratories in emerging economies, where diabetes is an increasingly significant public health issue, and is ideal for GP surgeries, diabetes clinics, and laboratories.

EKF’s new STAT-Site® M ß-HB will also be available for demonstrations. This new quantitative strip-based test for B-Hydroxybutyrate (BHB) is CE marked and provides a quick and easy assessment of diabetic ketoacidosis (DKA), delivering results in less than 80 seconds.

Using the STAT-Site® M ß-HB, the presence and degree of ketosis can be rapidly assessed at the point-of-care by accurately measuring blood levels of BHB, which accounts for 78% of the three ketone bodies, from just 10 µL of serum or plasma. This provides valuable information for providing quality care when monitoring DKA in newly diagnosed patients while reducing time and costs in an emergency room setting [1].

References:

• [1] M. Vanelli, G. Chiari, C. Capuano, B. Iovane, A. Bernardini, T. Giacalone. PubMed – October 2003.